SCHEMBL23880997

SCHEMBL23880997

CC(=O)c1ccc(-c2scnc2C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VHL P40337 4/20 0.60
PIK3CD O00329 2/20 0.50
PIK3CA P42336 2/20 0.50
PIK3CB P42338 2/20 0.50
PIK3CG P48736 2/20 0.50
PTGS1 P23219 1/20 0.45
BRD4 O60885 1/20 0.45
HSD17B1 P14061 2/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 2/20 0.42
PKM P14618 1/20 0.42
ALOX5 P09917 1/20 0.40
XDH P47989 1/20 0.39
FBP1 P09467 1/20 0.38
ELOC Q15369 1/20 0.38
ELOB Q15370 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28610139 0.85 VHL (0.55) VHLPTGS1KDM4EPKM
Hydrochloric Acid SCHEMBL28668471 0.83 VHL (0.54) VHLPTGS1KDM4EPKM
SCHEMBL24880893 0.83 VHL (0.52) VHLPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL23037352 0.81 VHL (0.51) VHLKDM4EPKMELOCELOB
SCHEMBL25006724 0.81 BRD4 (0.50) VHLBRD4KDM4E
SCHEMBL31017590 0.79 KMT2A (0.53) VHLSMN1; SMN2KDM4EPKMHPGD
SCHEMBL25473160 0.79 VHL (0.49) VHLPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL19600685 0.78 VHL (0.54) VHLMAPTSMN1; SMN2KDM4EPKM
SCHEMBL19661678 0.77 VHL (0.53) VHLMAPTSMN1; SMN2KDM4EPKM
SCHEMBL25201653 0.77 VHL (0.43) VHLPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 US disclosed
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF VHL, MDM2, CUL2 VHL 1/4885PIK3CD 2379/4885PIK3CA 1995/4885
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof VHL, MDM2, CUL2 VHL 1/4885PIK3CD 2379/4885PIK3CA 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.